Related references
Note: Only part of the references are listed.Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase.
Hongdo Do et al.
Oncotarget (2015)
Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer
Mark T. Fleming et al.
CLINICAL GENITOURINARY CANCER (2012)
A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
Tom Samuel Waddell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
J. A. Chan et al.
ANNALS OF ONCOLOGY (2011)
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
Ulrich Gatzemeier et al.
LANCET ONCOLOGY (2011)
Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients
Zacharenia Saridaki et al.
PLOS ONE (2011)
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
N. C. Tebbutt et al.
BRITISH JOURNAL OF CANCER (2010)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
A Phase 2 Study of Cetuximab in Combination With Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Nonsmall Cell Lung Cancer
Edward S. Kim et al.
CANCER (2009)
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples:: KRAS codon 12 and 13 mutations in non-small cell lung cancer
Michael Krypuy et al.
BMC CANCER (2006)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)